1800 519 711 | ltrpharma.com | [email protected] LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569) First ROXUS® Prescriptions Fulfilled in the United States 06 October 2026 Highlights • First patient-specific ROXUS® prescriptions received through Mavrox, Shed’s men’s...
First ROXUS Prescriptions Fulfilled in the United States
Filed with ASX · · 3 pages · English
Summary by 6ix AI
LTR Pharma Limited reports the fulfillment of the first patient-specific ROXUS prescriptions in the United States through a telehealth platform, Mavrox, and Strive Pharmacy's support for compounding and fulfillment. This milestone marks the beginning of ROXUS prescription activity under the agreements established with Shed and Strive Pharmacy. The company plans to continue supporting its U.S. partners as prescription activity increases.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
In the deck
Earlier from LTR Pharma
- SPONTAN Phase II Final Results
- FY26 Results Announcement
- SPONTAN Real-World Study Reports 93% Response
- LTR Executes U.S. Commercial Agreement with Strive
- LTR Executes Definitive U.S. Commercial Agreement with Shed
Later from LTR Pharma
- Australian-Developed ED Nasal Spray Now Being Prescribed in the U.S.
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow LTR Pharma into a list and get an email when it puts out news.
Follow LTR Pharma